SCHEMBL1035480

SCHEMBL1035480

COC(=O)c1ccc(F)cc1N

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.66
KDM4E B2RXH2 6/20 0.66
GAA P10253 5/20 0.66
HSD17B10 Q99714 3/20 0.66
MAPT P10636 3/20 0.66
HPGD P15428 3/20 0.66
GLA P06280 2/20 0.66
CASP1 P29466 1/20 0.66
CASP7 P55210 1/20 0.66
ATM Q13315 1/20 0.66
ABL1 P00519 1/20 0.64
CFTR P13569 3/20 0.63
IKBKB O14920 1/20 0.49
ALOX15 P16050 1/20 0.49
TSHR P16473 1/20 0.49
SLC6A4 P31645 1/20 0.47
SLC6A3 Q01959 1/20 0.47
KEAP1 Q14145 1/20 0.47
NPC1 O15118 1/20 0.46
CASP3 P42574 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7729822 0.98 ALDH1A1 (0.64) ALDH1A1KDM4EGAAHSD17B10MAPT
SCHEMBL21857075 0.86 ALDH1A1 (0.58) ALDH1A1KDM4EGAAHSD17B10MAPT
SCHEMBL165608 0.85 ALDH1A1 (0.62) ALDH1A1KDM4EGAAHSD17B10MAPT
SCHEMBL23540246 0.83 KDM4E (0.51) ALDH1A1KDM4EGAAHSD17B10MAPT
SCHEMBL29654804 0.83 KDM4E (0.51) ALDH1A1KDM4EGAAHSD17B10MAPT
SCHEMBL3726926 0.83 ALDH1A1 (0.48) ALDH1A1KDM4EGAAHSD17B10MAPT
SCHEMBL30301996 0.82 SLC6A4 (0.51) ALDH1A1KDM4EGAAHSD17B10MAPT
SCHEMBL2708451 0.82 SLC6A4 (0.51) ALDH1A1KDM4EGAAHSD17B10MAPT
SCHEMBL1559630 0.82 HDAC1 (0.46) ALDH1A1KDM4EGAAHSD17B10MAPT
SCHEMBL16353322 0.82 KDM4E (0.83) ALDH1A1KDM4EGAAHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1351946-A2 MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT ICOS CORPORATION (US) 2003-10-15 EP claimed
US-20020165218-A1 Materials and methods to potentiate cancer treatment LUITPOLD PHARMACEUTICALS, INC. 2002-11-07 US claimed
WO-2002020500-A2 MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT ICOS CORPORATION (US) 2002-03-14 WO claimed
US-12606522-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives ORSOBIO, INC. (US) 2026-04-21 US disclosed
US-20250213575-A1 8-HETEROCYCLIC-3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES AS ANTI-BACTERIALS BioVersys AG (CH) 2025-07-03 US disclosed
WO-2025136936-A1 AGONISTS OF TREM2 ACTIVITY MERCK SHARP & DOHME LLC (US) 2025-06-26 WO disclosed
US-20250197413-A1 RXFP1 RECEPTOR AGONISTS ELI LILLY AND COMPANY 2025-06-19 US disclosed
WO-2025128938-A1 BENZOTHIAZOLE DERIVATIVES USEFUL AS RXFP1 RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2025-06-19 WO disclosed
CN-120117999-A Fluorotranilast derivatives and medical application thereof 中国药科大学 2025-06-10 CN disclosed
CN-119143671-B Method for simply and conveniently synthesizing quinolinone derivative through one-pot method of carboinsertion reaction 九洲药业(杭州)有限公司 2025-05-16 CN disclosed
EP-4543884-A1 8-HETEROCYCLIC-3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES AS ANTI-BACTERIALS BioVersys AG (CH) 2025-04-30 EP disclosed
US-5739133-A N-ACYLATED AND ALKYLATED DERIVATIVES OF PYRIDAZINO(4,5-B)-QUINOLINES; EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS; STROKES; ANTIISCHEMIC AND HYPOGLYCEMIC AGENTS; PSYCHOSIS; NEUROGODEGENERATIVE DISORDERS ZENECA LIMITED (GB) 1998-04-14 US disclosed
US-5733910-A Pyridazinedione compounds useful in the treating neurological disorders IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1998-03-31 US disclosed
US-5604227-A EXCITATORY AMINO ACID ANTAGONIST; MONO, DI OR TRI-ACETYLATION OR ALKYLATION IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1997-02-18 US disclosed
US-5599814-A SUBSTITUTED PYRIDAZINO(4,5-B)QUINOLINES AS ANTAGONISTS OF EXCITATORY AMINO ACIDS IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) 1997-02-04 US disclosed
EP-0516297-B1 Pyridazinediones and their use in the treatment of neurological disorders ZENECA LTD (GB) 1996-10-30 EP disclosed
EP-0516297-A1 Pyridazinediones and their use in the treatment of neurological disorders ZENECA LIMITED (GB) 1992-12-02 EP disclosed
US-5093364-A 5-FLUOROANTHRANILIC FUNGICIDES SCHERING AGROCHEMICALS LIMITED (GB) 1992-03-03 US disclosed
EP-0360417-A2 Derivatives of 4-fluoroanthranilic acid and their use as fungicides SCHERING AGROCHEMICALS LIMITED (GB) 1990-03-28 EP disclosed
US-4198350-A Amination/demethylation process STANDARD OIL COMPANY (INDIANA) (US) 1980-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250197413-A1 RXFP1 RECEPTOR AGONISTS RXFP1, RXFP3, RXFP2 ALDH1A1 1973/4885KDM4E 3828/4885GAA 3322/4885
US-20250213575-A1 8-HETEROCYCLIC-3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES AS ANTI-BACTERIALS CUTA, AP1S1, SUB1 ALDH1A1 3861/4885KDM4E 1939/4885GAA 3404/4885
US-12606522-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives NR3C2, NR5A1, SRD5A2 ALDH1A1 1507/4885KDM4E 3921/4885GAA 2559/4885
US-20020165218-A1 Materials and methods to potentiate cancer treatment DCK, CHEK2, CHEK1 ALDH1A1 3519/4885KDM4E 2518/4885GAA 1233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.